New treatment option for adult-onset limbal xanthogranuloma.
OBJECTIVE
The purposes of this study are to report a case of adult-onset juvenile xanthogranuloma and suggest a new treatment option.


METHODS
A 35-year-old man presented with an isolated mass of the limbus. Biopsy revealed a histiocytic tumor with Touton's giant cells staining positive for CD68 and S-100 but negative for CD1a, consistent with JXG. Two intratumoral injections of triamcinolone acetonide 6 weeks apart were performed. The main outcome measure was 6-months follow up clinically and by ultrasound biomicroscopy.


RESULTS
The lesion regressed, and corneal thickness returned to normal 3 months after the first injection. An increase in intraocular pressure required topical treatment. No recurrence was seen throughout follow up.


CONCLUSIONS
Limbal juvenile xanthogranuloma can be successfully treated with intralesional triamcinolone acetonide, thus avoiding a lamellar keratectomy approach.
Hermel
Martin
M
Department of Ophthalmology, RWTH Aachen University, Aachen, Germany. mhermel@ukaachen.de
Donner
Andreas
A
Remky
Andreas
A
D000328:Adult; D015415:Biomarkers / Q000378:metabolism; D003316:Corneal Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D015552:Injections, Intralesional; D016850:Limbus Corneae / Q000473:pathology*; D008297:Male; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014972:Xanthogranuloma, Juvenile / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
D015415:Biomarkers; D005938:Glucocorticoids; D014222:Triamcinolone Acetonide